{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03226249","nct_id":"NCT03226249","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03226249. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"See Detailed Description","label":"Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2024-10","type":"ESTIMATED"},"conditions":["Classical Hodgkin Lymphoma","Lymphocyte-Depleted Classical Hodgkin Lymphoma","Lymphocyte-Rich Classical Hodgkin Lymphoma","Mixed Cellularity Classical Hodgkin Lymphoma","Nodular Sclerosis Classical Hodgkin Lymphoma"],"enrollment":{"count":30,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computerized Axial Tomography","computerized tomography","CT","CT SCAN","tomography"],"type":"PROCEDURE"},{"name":"Dacarbazine","otherNames":["4-(Dimethyltriazeno)imidazole-5-carboxamide","5-(Dimethyltriazeno)imidazole-4-carboxamide","Asercit","Biocarbazine","Dacarbazina","Dacarbazina Almirall","Dacarbazine - DTIC","Dacatic","Dakarbazin","Deticene","Detimedac","DIC","Dimethyl (triazeno) imidazolecarboxamide","Dimethyl Triazeno Imidazol Carboxamide","Dimethyl Triazeno Imidazole Carboxamide","dimethyl-triazeno-imidazole carboxamide","Dimethyl-triazeno-imidazole-carboximide","DTIC","DTIC-Dome","Fauldetic","Imidazole Carboxamide","Imidazole Carboxamide Dimethyltriazeno","WR-139007"],"type":"DRUG"},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"],"type":"DRUG"},{"name":"Fludeoxyglucose F-18","otherNames":["18FDG","FDG","fludeoxyglucose F 18","Fludeoxyglucose F18","Fluorine-18 2-Fluoro-2-deoxy-D-Glucose","Fluorodeoxyglucose F18"],"type":"RADIATION"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Pembrolizumab","otherNames":["Keytruda","Lambrolizumab","MK-3475","SCH 900475"],"type":"BIOLOGICAL"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging"],"type":"PROCEDURE"},{"name":"Vinblastine Sulfate","otherNames":["29060 LE","29060-LE","Exal","Velban","Velbe","Velsar","VINCALEUKOBLASTINE"],"type":"DRUG"}],"last_update":"2023-06-02","lead_sponsor":"Northwestern University","official_title":"Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2019-05-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Response (CR) With Pembrolizumab Treatment Alone","timeFrame":"After 3 cycles of pembrolizumab (1 cycle = 21 days)"}],"references":[{"citation":"Kreuzberger N, Goldkuhle M, von Tresckow B, Kobe C, Sickinger MT, Monsef I, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3.","pmid":"40135712","type":"DERIVED"},{"citation":"Allen PB, Lu X, Chen Q, O'Shea K, Chmiel JS, Slonim LB, Sukhanova M, Savas H, Evens AM, Advani R, Pro B, Karmali R, Palmer B, Bayer RA, Eisner RM, Mou E, Dillehay G, Gordon LI, Winter JN. Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv. 2023 Jun 27;7(12):2670-2676. doi: 10.1182/bloodadvances.2022008116.","pmid":"36083129","type":"DERIVED"},{"citation":"Allen PB, Savas H, Evens AM, Advani RH, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer RA, Eisner RM, Chmiel JS, O'Shea K, Gordon LI, Winter JN. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 2021 Mar 11;137(10):1318-1326. doi: 10.1182/blood.2020007400.","pmid":"32992341","type":"DERIVED"}],"start_date":{"date":"2017-11-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT03226249"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03226249"}